

ASX ANNOUNCEMENT

MIDKINE INTERVIEWS WITH PHARMATELEVISION PUBLISHED

- **Interviews recorded by PharmaTelevision® at Cellmid's 4th Midkine Symposium are now published**
- **Nine interviews with attending scientists and senior industry figures are available to the public**
- **Interviews provide further insight into the ongoing value creation in the midkine programs**

SYDNEY, 29 June 2016: Cellmid Limited (ASX: CDY) is pleased to advise that the interviews recorded by PharmaTelevision® during the 4th Midkine Symposium held in April 2016 have now been released for broadcast. Interviews can be accessed on Cellmid's website by following the link:

http://www.cellmid.com.au/content_common/pg-pharmatelevision-midkine-symposium-2016.seo

PharmaTelevision® attended the 4th Midkine Symposium and recorded nine interviews with key delegates, and Cellmid collaborators, on MK research and on translating medical research into clinical benefit to patients. PharmaTelevision®, based in Oxford UK, has been the leading online news channel for the biopharma industry since 2006. With a global audience of 18,000+, including senior industry executives, PharmaTelevision® channels include News Review featuring interviews with experts.

In addition to industry information, the interviews provide substantial further details, given by the scientists, on some of the cutting edge research into MK pursued by Cellmid collaborators around the world. The following topics are addressed in the interviews:

1. **Maria Halasz, CEO and Managing Director of Cellmid** discusses the Midkine Symposium and the company's strategy around chronic kidney disease (CKD) and related complications and acute myocardial infarction (AMI).
2. **The discoverers of midkine, Emeritus Professor Takashi Muramatsu and Professor Kenji Kadomatsu** (Nagoya University Japan), describe the research leading to the discovery of the protein and its particular role in neural growth and cancers.
3. **Dr Victoria Campbell, Intensive Care Specialist and Nephrologist** (Nambour General Hospital, Queensland) discusses the role of midkine in chronic kidney disease (CKD).
4. **Professor Peter Ferdinandy, CEO, Pharmahungary Group and Professor of Pharmacology and Clinical Pharmacology** (Semmelweis University, Budapest, Hungary), describes the role of midkine in treating post-ischemic injury in myocardial infarction.

5. **Professor Guillermo Velasco, Associate Professor of Biochemistry and Molecular Biology** (Complutense University, Madrid, Spain), explains how blocking midkine signaling could facilitate the treatment of aggressive brain cancers including glioblastoma.
6. **Professor Gonzalo Herradon, Associate Professor of Pharmacology** (Universidad CEU San Pablo, Madrid, Spain), discusses the effect of pleiotrophin (a molecule in the midkine family) in regulating the neuro-toxic effects of drugs and alcohol and in pathways of addiction.
7. **Professor Evangelia Papadimitriou, Professor of Molecular Pharmacology** (Department of Pharmacy, School of Health Sciences, University of Patras, Greece), describes the pro and anti-angiogenic properties of pleiotrophin and the development of novel molecules to supplement existing anti-angiogenic therapies.
8. **Dr Esther Gramage, Assistant Professor of Pharmacology and Toxicology** (University CEU San Pablo, Madrid, Spain), discusses the role of midkine in the process of neural regeneration using a zebra fish retina model.
9. **Professor Richard Barker, Founding Director, Centre for the Advancement of Sustainable Medical Innovation** (Oxford, UK), reviews the need to translate our rapidly growing understanding of bioscience into more patient-focused product delivery.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to this novel target is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.